Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam

European Neuropsychopharmacology

Volumn 21, Issue 4, 2011, Pages 325-332

  Leggio, Gian Marco ^a   Micale, Vincenzo ^a   Le Foll, Bernard ^b   Mazzola, Carmen ^a   Nobrega, José N ^b   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diazepam; Dopamine D3 dopamine receptor; Elevated plus maze test; GABAA receptor binding; Knock out mice; Novelty induced grooming sampling test

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 4 AMINOBUTYRIC ACID A RECEPTOR; DIAZEPAM; DOPAMINE 3 RECEPTOR; FLUNITRAZEPAM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; GROOMING; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; GROOMING; MALE; MICE; MICE, KNOCKOUT; MOOD DISORDERS; NERVE TISSUE PROTEINS; NEURONS; ORGAN SPECIFICITY; RANDOM ALLOCATION; RECEPTORS, DOPAMINE D3; RECEPTORS, GABA-A; TIME FACTORS;

EID: 79952362652     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.05.006     Document Type: Article

References (55)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. PNAS 1996, 93:1945-1949.
2. Archer J. Tests for emotionality in rats and mice: a review. Anim. Behav. 1973, 21:205-235.
3. Bartoszyk G.D. Anxiolytic effects of dopamine receptor ligands: involvement of dopamine autoreceptors. Life Sci. 1998, 62:649-663.
4. Betancur C., Lepee-Lorgeoux I., Cazillis M., Accili D., Fuchs S., Rostene W. Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice. Neuropsychopharmacology 2001, 24:170-182.
5. Bolles R.C. Grooming behavior in the rat. J. Comp. Physiol. Psychol. 1960, 53:306-310.
6. Boulay D., Depoortere R., Perrault G., Borrelli E., Sanger D.J. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology 1999, 38:1389-1396.
7. Boulay D., Depoortere R., Rostene W., Perrault G., Sanger D.J. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 1999, 38:555-565.
8. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991, 564:203-219.
9. Cabib S., Puglisi-Allegra S. Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J. Neurosci. 1994, 14:3333-3340.
10. Chen G., Kittler J.T., Moss S.J., Yan Z. Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J. Neurosci. 2006, 2625:13-21.
11. Clement Y., Calatayud F., Belzung C. Genetic basis of anxiety-like behaviour: a critical review. Brain Res. Bull. 2002, 57:57-71.
12. Costall B., Hendrie C.A., Kelly M.E., Naylor R.J. Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology 1987, 26:195-200.
13. David D.J., Bourin M., Jego G., Przybylski C., Jolliet P., Gardier A.M. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br. J. Pharmacol. 2003, 140:1128-1136.
14. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
15. Drago F., Canonico P.L., Bitetti R., Scapagnini U. Systemic and intraventricular prolactin induces excessive grooming. Eur. J. Pharmacol. 1980, 65:457-458.
16. Dunn A.J. Stress-related activation of cerebral dopaminergic systems. Ann N Y Acad Sci 1988, 537:188-205.
17. Fentress J.C. Development of grooming in mice with amputated forelimbs. Science 1973, 179:704-705.
18. File S.E. Usefulness of animal models with newer anxiolytics. Clin. Neuropharmacol. 1992, 15:525A-526A.
19. Finlay J.M., Zigmond M.J., Abercrombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience 1995, 64:619-628.
20. Floran B., Aceves J., Sierra A., Martinez-Fong D. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci. Lett. 1990, 116:136-140.
21. Gao B., Cutler M.G., Gao B. Buspirone increases social investigation in pair-housed male mice; comparison with the effects of chlordiazepoxide. Neuropharmacology 1993, 32:429-437.
22. Gendreau P.L., Petitto J.M., Schnauss R., Frantz K.J., Van Hartesveldt C., Gariepy J.L., Lewis M.H. Effects of the putative dopamine D3 receptor antagonist PNU 99194A on motor behavior and emotional reactivity in C57BL/6J mice. Eur. J. Pharmacol. 1997, 337:147-155.
23. Gispen W.H., Isaacson R.L. ACTH-induced excessive grooming in the rat. Pharmaco. The. 1981, 12:209-246.
24. Griebel G., Belzung C., Perrault G., Sanger D.J. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 2000, 148:164-170.
25. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002, 112:39-49.
26. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 1998, 18:2231-2238.
27. Le Foll B., Diaz J., Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci. 2005, 76:1281-1296.
28. Le Foll B., Frances H., Diaz J., Schwartz J.C., Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 2002, 15:2016-2026.
29. Leggio G.M., Micale V., Drago F. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur. Neuropsychopharmacol. 2008, 18:271-277.
30. Lepicard E.M., Joubert C., Hagneau I., Perez-Diaz F., Chapouthier G. Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Pharmacol. Biochem. Behav. 2000, 67:739-748.
31. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49:231-252.
32. Lister R.G. The effects of ethanol on exploration in DBA/2 and C57Bl/6 mice. Alcohol 1987, 4:17-19.
33. Lister R.G. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 1990, 46:321-340.
34. Mayfield D.R., Larson G., Orona R.A., Zahniser N.R. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse 1996, 22:132-138.
35. Mercuri N.B., Saiardi A., Bonci A., Picetti R., Calabresi P., Bernardi G., Borrelli E. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997, 79:323-327.
36. Metha A.K., Ticku M.K. An update on GABAA receptors. Brain Res. Rev. 1999, 29:196-217.
37. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., Di Marzo V. Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: possible involvement of the endocannabinoid and endovanilloid systems. Neurobiol. Dis. 2009, 36(1):70-80.
38. Navarro J.F., Luna G., García F., Pedraza C. Effects of L-741, 741, a selective dopamine receptor antagonist, on anxiety tested in the elevated plus-maze in mice. Meth. Find. Exp. Clin. Pharmacol. 2003, 25:45-47.
39. Pellow S., Chopin P., File S.E. Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors?. Neurosci. Lett. 1985, 55:5-9.
40. Pich E.M., Samanin R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology 1986, 89:125-130.
41. Plaznik A., Kostowski W., Stefanski R. Limbic mechanisms of anxiolytics acting on 5-HT receptors. Pol. J. Pharmacol. 1995, 46:473-477.
42. Pritchard L.M., Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., et al. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 2003, 28:100-107.
43. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology (Berl) 2001, 159:42-50.
44. Rodgers R.J., Nikulina E.M., Cole J.C. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 1994, 49:985-995.
45. Rogóz Z., Klodzinska A., Maj J. Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models. Pol. J. Pharmacol. 2000, 52:459-462.
46. Rogóz Z., Skuza G., Klodzinska A. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Pol. J. Pharmacol. 2003, 55:449-454.
47. Schmitz Y., Schmauss C., Sulzer D. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J. Neurosci. 2002, 22:8002-8009.
48. Seeman P., Sunahara R.K., Niznik H.B. Receptor-receptor link in membranes revealed by ligand competition: example for dopamine D1 and D2 receptors. Synapse 1994, 17:62-64.
49. Simon P., Panissaud C., Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol. Biochem. Behav. 1993, 45:685-690.
50. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 2006, 5:25-43.
51. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
52. Stefanski R., Palejko W., Bidzinski A., Kostowski W., Plaznik A. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists. Neuropharmacology 1993, 32:987-993.
53. Steiner H., Fuchs S., Accili D. D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol. Behav. 1998, 63:137-141.
54. Waddington J.L., Clifford J.J., McNamara F.N., Tomiyama K., Koshikawa N., Croke D.T. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:925-964.
55. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19:837-848.